The evolving landscape in the therapy of acute myeloid leukemia
-
Published:2013-08-27
Issue:10
Volume:4
Page:735-746
-
ISSN:1674-800X
-
Container-title:Protein & Cell
-
language:en
-
Short-container-title:Protein Cell
Author:
Peloquin Grace L.,Chen Yi-Bin,Fathi Amir T.
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Drug Discovery,Biochemistry,Biotechnology
Reference111 articles.
1. Amann, J. M., Nip, J., Strom, D. K., Lutterbach, B., Harada, H., Lenny, N., Downing, J.R., Meyers, S., and Hiebert, S. W. (2001). ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol 21, 6470–6483. 2. Appelbaum, F. R., Gundacker, H., Head, D. R., Slovak, M. L., Willman, C. L., Godwin, J. E., Anderson, J. E., and Petersdorf, S. H. (2006). Age and acute myeloid leukemia. Blood 107, 3481–3485. 3. Arlin, Z., Case, D. C., Moore, J., Wiernik, P., Feldman, E., Saletan, S., Desai, P., Sia, L., and Cartwright, K. (1990). Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. Leukemia 4, 177–183. 4. Barjesteh van Waalwijk van Doorn-Khosrovani, S., Erpelinck, C., Meijer, J., van Oosterhoud, S., van Putten, W. L., Valk, P. J., Berna Beverloo, H., Tenen, D. G., Lowenberg, B., and Delwel, R. (2003). Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J 4, 31–40. 5. Bello, C., Yu, D., Komrokji, R. S., Zhu, W., Wetzstein, G. A., List, A. F., and Lancet, J. E. (2011). Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer 117, 1463–1469.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|